Bristol-Myers Squibb Company (BMY)
7 Dividend Stocks to Buy Now: June 2024
Income-oriented investors love finding dividend stocks to buy now. That's particularly true when those stocks are on sale, as many continue to be.
3 High-Yield Dividend Stocks Near Their 52-Week Lows to Buy and Hold
Pfizer has a lot of new drugs on the market, but its stock has been beaten down. Johnson & Johnson stock is down even though both its medical technology and pharmaceutical businesses reported significant gains this year.
US FDA approves Bristol Myers' colorectal cancer therapy
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's combination therapy for treating colorectal cancer in patients with a specific gene mutation, the health regulator's website showed on Friday.
3 Warren Buffett Stocks to Buy Now: June 2024
Investors continue to look for the market to broaden before jumping in. They may be waiting awhile.
6 of Wall Street's Favorite High-Yield Blue Chip Dividend Stocks to Buy in June
24/7 Insights Quality dividend stocks can generate solid total returns and yield passive income.
3 High-Yield S&P 500 Dividend Stocks Down More Than 25% to Buy Now and Hold for at Least a Decade
Pfizer stock has been beaten down so far that it offers a dividend yield above 6% at recent prices. Bristol Myers Squibb has been trading for the low multiple of about 7 times trailing free cash flow.
Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Augtyro
The FDA approves Bristol Myers' (BMY) cancer drug Augtyro for the treatment of adult and pediatric patients aged 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.
3 High-Yield Dividend Stocks for Income Now and Growth Later
The latest readings on inflation show some cooling, and stocks seem to like it. However, it's important to be clear about why investors feel bullish.
Bristol-Myers Squibb: Move Investing Time Horizon To 2025, At Least
Bristol-Myers Squibb Company stock has taken a big tumble in the past quarter following its sharply reduced earnings guidance, but there are still plenty of positives going for it. Better than expected revenue growth in Q1 2024, earnings reduction being restricted to one year only and its recent cost reduction initiatives indicate better times from 2025 onwards. Its still elevated forward P/E indicates it's unlikely to see an uptick anytime this year, but it's still a good time to start buying the stock for next year.
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Dividend Harvesting Portfolio Week 171: $17,100 Allocated, $1,524.12 In Projected Dividends
The markets had a strong week, with the S&P 500 gaining 0.97% and the Dow Jones Industrial Average gaining 1.6%. Yields on the 10-year Treasury shot up to 4.9% ahead of the FOMC meeting. The Dividend Harvesting Portfolio traded sideways but continues to generate consistent dividend income and exceed invested capital.
Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb
Key scientific achievement advances the joint pipeline in the strategic neuroscience partnership with Bristol Myers Squibb and earns a payment of US$ 20 m to Evotec to progress further research HAMBURG, GERMANY / ACCESSWIRE / June 12, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced today that the Company has reached important scientific progress within its neuroscience collaboration with Bristol Myers Squibb (NYSE:BMY) triggering a research payment of US$ 20 m to Evotec. A target-based programme progresses into late pre-clinical development, further contributing to the fast-growing and promising pipeline of discovery to clinical-stage programmes in neurodegeneration that the partnership has generated.
